Legend Biotech (LEGN) Competitors $38.80 -0.27 (-0.69%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$38.81 +0.01 (+0.03%) As of 08/1/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEGN vs. BNTX, SMMT, INSM, TEVA, GMAB, MRNA, RDY, QGEN, VTRS, and ASNDShould you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Legend Biotech vs. Its Competitors BioNTech Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S Legend Biotech (NASDAQ:LEGN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk. Does the media favor LEGN or BNTX? In the previous week, BioNTech had 5 more articles in the media than Legend Biotech. MarketBeat recorded 10 mentions for BioNTech and 5 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.08 beat BioNTech's score of 0.88 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, LEGN or BNTX? Legend Biotech has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Is LEGN or BNTX more profitable? BioNTech has a net margin of -27.37% compared to Legend Biotech's net margin of -29.95%. BioNTech's return on equity of -3.94% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-29.95% -21.19% -13.47% BioNTech -27.37%-3.94%-3.41% Do analysts rate LEGN or BNTX? Legend Biotech currently has a consensus target price of $73.33, suggesting a potential upside of 89.00%. BioNTech has a consensus target price of $136.58, suggesting a potential upside of 27.24%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.76 Which has higher earnings and valuation, LEGN or BNTX? Legend Biotech has higher earnings, but lower revenue than BioNTech. Legend Biotech is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$627.24M11.37-$177.03M-$0.59-65.76BioNTech$2.98B8.67-$719.92M-$3.40-31.57 Do insiders and institutionals have more ownership in LEGN or BNTX? 70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryBioNTech beats Legend Biotech on 9 of the 16 factors compared between the two stocks. Get Legend Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEGN vs. The Competition Export to ExcelMetricLegend BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.18B$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-65.7617.6228.7823.81Price / Sales11.37179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book6.818.508.275.54Net Income-$177.03M-$55.06M$3.25B$259.28M7 Day Performance-10.52%-3.99%-3.70%-4.64%1 Month Performance8.05%9.58%4.34%4.41%1 Year Performance-29.04%6.70%25.90%17.95% Legend Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEGNLegend Biotech3.5917 of 5 stars$38.80-0.7%$73.33+89.0%-29.5%$7.18B$627.24M-65.762,609Positive NewsBNTXBioNTech2.7516 of 5 stars$112.79-2.2%$136.58+21.1%+33.0%$27.11B$2.98B-33.176,772Upcoming EarningsGap DownSMMTSummit Therapeutics2.8961 of 5 stars$27.45-4.3%$34.67+26.3%+153.9%$20.39B$700K-80.73110Positive NewsUpcoming EarningsINSMInsmed3.8031 of 5 stars$101.75-2.1%$109.20+7.3%+44.3%$19.30B$363.71M-17.101,271Positive NewsUpcoming EarningsTEVATeva Pharmaceutical Industries3.9815 of 5 stars$16.53-0.1%$24.71+49.5%-12.3%$18.96B$16.62B-14.3736,830News CoveragePositive NewsEarnings ReportGMABGenmab A/S3.5091 of 5 stars$23.09-1.3%$37.80+63.7%-23.2%$14.81B$3.12B13.122,682News CoveragePositive NewsShort Interest ↑MRNAModerna4.4709 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.11B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownRDYDr. Reddy's Laboratories1.9785 of 5 stars$14.71+0.2%$16.95+15.3%-15.5%$12.28B$3.81B22.2827,811QGENQiagen3.2221 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.34B$1.98B127.875,765News CoverageUpcoming EarningsVTRSViatris2.2182 of 5 stars$9.26-1.6%$10.40+12.3%-26.3%$10.87B$14.74B-2.9232,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0931 of 5 stars$164.16-2.0%$223.07+35.9%+27.8%$10.04B$368.70M-26.141,017Analyst Forecast Related Companies and Tools Related Companies BNTX Alternatives SMMT Alternatives INSM Alternatives TEVA Alternatives GMAB Alternatives MRNA Alternatives RDY Alternatives QGEN Alternatives VTRS Alternatives ASND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEGN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Corporation Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
